RAPP
HEALTHCARERapport Therapeutics, Inc. Common Stock
What's Moving RAPP Today?
No stock-specific AI insight has been generated for RAPP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$38.88
Fundamentals
Trading
RAPP News
21 articles- Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?Yahoo Finance·Jun 16, 2026
- Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?Yahoo Finance·Jun 8, 2026
- BTIG Raises its Price Target on Rapport Therapeutics (RAPP)Yahoo Finance·Jun 5, 2026
- Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·May 20, 2026
- Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure MarketTipRanks·May 7, 2026
- Rapport Therapeutics, Inc. (RAPP) Reports Q1 LossYahoo Finance·May 7, 2026
- Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business UpdateYahoo Finance·May 7, 2026
- Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their HoldingsYahoo Finance·Apr 30, 2026
- Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials NearMotley Fool·Apr 27, 2026
- Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual MeetingYahoo Finance·Apr 21, 2026
- Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual MeetingGlobeNewswire Inc.·Apr 1, 2026
- All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to BuyYahoo Finance·Mar 26, 2026
- How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater ChinaYahoo Finance·Mar 21, 2026
- This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover DealMotley Fool·Mar 16, 2026
- Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 LaunchMotley Fool·Mar 16, 2026
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last QuarterMotley Fool·Mar 16, 2026
- Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 10, 2026
- Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater ChinaYahoo Finance·Mar 9, 2026
- Rapport Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 24, 2026
- We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn RateYahoo Finance·Feb 18, 2026
- Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff?Yahoo Finance·Jan 9, 2026
All 21 articles loaded
Price Data
52-Week Range
$38.88
Fundamentals
Trading
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing transformative therapeutics aimed at neurodegenerative diseases, with a primary focus on Alzheimer's disease and related cognitive disorders. Utilizing proprietary drug candidates and cutting-edge technology platforms, the company drives innovation through robust scientific research and clinical trials. By targeting critical unmet medical needs in neurodegeneration, Rapport Therapeutics is strategically positioned to make significant contributions to the treatment landscape, potentially enhancing the quality of life for patients afflicted by debilitating cognitive impairments.